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Abstract
Background: The 70 kDa ribosomal protein S6 kinase (RPS6KB1), located at 17q23, is amplified
and overexpressed in 10–30% of primary breast cancers and breast cancer cell lines. p70S6K is a
serine/threonine kinase regulated by PI3K/mTOR pathway, which plays a crucial role in control of
cell cycle, growth and survival. Our aim was to determine p70S6K and PI3K/mTOR/p70S6K
pathway dependent gene expression profiles by microarrays using five breast cancer cell lines with
predefined gene copy number and gene expression alterations. The p70S6K dependent profiles
were determined by siRNA silencing of RPS6KB1 in two breast cancer cell lines overexpressing
p70S6K. These profiles were further correlated with gene expression alterations caused by
inhibition of PI3K/mTOR pathway with PI3K inhibitor Ly294002 or mTOR inhibitor rapamycin.
Results: Altogether, the silencing of p70S6K altered the expression of 109 and 173 genes in two
breast cancer cell lines and 67 genes were altered in both cell lines in addition to RPS6KB1.
Furthermore, 17 genes including VTCN1 and CDKN2B showed overlap with genes differentially
expressed after PI3K or mTOR inhibition. The gene expression signatures responsive to both PI3K/
mTOR pathway and p70S6K inhibitions revealed previously unidentified genes suggesting novel
downstream targets for PI3K/mTOR/p70S6K pathway.
Conclusion:  Since p70S6K overexpression is associated with aggressive disease and poor
prognosis of breast cancer patients, the potential downstream targets of p70S6K and the whole
PI3K/mTOR/p70S6K pathway identified in our study may have diagnostic value.
Background
The 70 kDa ribosomal protein S6 kinase (p70S6K) is a
mitogen-activated serine/threonine kinase that has a criti-
cal role in control of cell cycle, growth and survival.
p70S6K is encoded by RPS6KB1, which is located at
17q23 and is amplified and overexpressed in 10–30% of
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breast cancer cell lines and primary breast cancers [1-4].
The overexpression of p70S6K is associated with aggres-
sive disease and poor prognosis of breast cancer patients
[2]. p70S6 kinase is located downstream of PI3K/AKT/
mTOR pathway, which is activated by HER2 receptors,
insulin-like growth factor receptor and estrogen receptor
in breast cancer [5]. p70S6K itself is activated by 3-phos-
phoinositide-dependent protein kinase 1 (PDK-1) and
mammalian target of rapamycin (mTOR) kinase. p70S6
kinase regulates protein synthesis by activating 40S ribos-
omal protein S6, leading to an increased rate of transla-
tion of the class of 5'TOP (5' terminal oligopyrimide)
mRNA transcripts. These transcripts encode critical com-
ponents of the cellular translational machinery, thus pro-
moting protein synthesis [6,7]. Additionally, p70S6K has
a crucial role in cell growth by regulating cell size and pro-
gression of cell cycle [8-10]. Recently, p70S6K has been
reported to inactivate the pro-apoptotic molecule BAD by
phosphorylation, thereby also promoting cell survival
[11].
PI3K/AKT/mTOR pathway is often activated in cancer due
to genetic alterations of the genes implicated in this path-
way. For example, PIK3CA, PTEN, TSC1/2, HER2, AKT,
and PDPK1 have been found to be frequently mutated or
amplified in cancer and thereby PI3K/AKT/mTOR path-
way is an attractive target for therapeutics. In clinical trials,
there are a number of drugs that target proteins involved
in this pathway [12,13]. For example, flavonoid derivative
Ly294002 is a PI3K inhibitor that acts in the ATP-binding
site of PI3K enzyme and targets the PI3K/AKT axis [14].
Rapamycin is an immunosuppressant and a potential
clinical drug that inhibits mTOR by binding to the phos-
phatidic acid-binding site required for mTOR activation
[15,16]. Thus, mTOR cannot phosphorylate p70S6 kinase
resulting in G1 arrest of the cell cycle and suppression of
protein synthesis. Despite the fact that PI3K/AKT/mTOR
pathway contains many putative therapeutic targets, the
clinical trials with the pathway-specific drugs have not
been as promising as previously thought. This might be
due to the cross-talk of PI3K/AKT/mTOR pathway with
multiple other signalling pathways leading to multiple
sites of regulation. Similarly, the diversity of genetic aber-
rations activating this pathway is likely to cause differ-
ences in drug responses.
Our aim was to identify genes that are transcriptionally
altered due to PI3K/mTOR/p70S6K pathway inhibition in
breast cancer cells using RNAi and small molecule inhibi-
tors. p70S6K encoded by RPS6KB1 was knocked down
using three different siRNAs in BT-474 and MCF-7 breast
cancer cell lines, since these cell lines show high-level
amplification and overexpression of RPS6KB1. Ly294002
and rapamycin are known to target PI3K/mTOR pathway
upstream of p70S6K. Therefore, breast cancer cell lines
BT-474, MCF-7, MDA-361, MDA-436 and SK-BR-3 were
treated with these inhibitors to compare transcriptional
signatures responsive to both RPS6KB1 and PI3K/mTOR
pathway inhibitions. Our results show for the first time
the genome-wide transcriptional consequences of PI3K/
mTOR pathway and RPS6KB1 inhibitions in breast can-
cer, suggesting novel downstream targets for PI3K/mTOR
pathway and p70S6 kinase.
Results
p70S6K suppression induces specific gene expression 
alterations
To identify downstream targets of p70S6K in breast cancer
cells, we first examined gene expression alterations in
RPS6KB1-suppressed BT-474 and MCF-7 breast cancer cell
lines that normally show high-level expression of p70S6K.
We used three different siRNAs to knock-down the expres-
sion of RPS6KB1 (Figure 1). Based on the microarray anal-
yses, the signal log10 ratio with siRNA 1 was -0.5,
resulting in 70% relative downregulation of RPS6KB1
mRNA, whereas with RPS6KB1  siRNAs 2 and 3 log10
ratios were -0.3 – -0.5 with different probes representing
RPS6KB1, indicating 50–70% relative suppression with
these two siRNAs. The signal log10 ratios of all the genes
representing their mRNA expression levels are available at
CanGEM (please see Availability & requirements for more
information). The RPS6KB1 knock-down also caused sig-
nificant decrease in p70S6K protein expression after 72
hours in both cell lines (Figure 2).
The microarray analyses showed that altogether 109 and
173 genes displayed over two-fold difference with at least
two different RPS6KB1  siRNAs in BT-474 and MCF-7
breast cancer cell lines, respectively. Of these differentially
expressed genes, 68 genes (39–62%) were commonly
down- or up-regulated in both cell lines including
RPS6KB1,  ABL1,  PPP1R12B,  PRKCQ, and STK32B  [see
Additional File 1]. Sixty-nine genes (63%) were down- or
up-regulated in BT-474 with all three siRNAs, whereas
ninety-one genes (53%) were differentially expressed with
all siRNAs in MCF-7. From these, 45 genes were differen-
tially expressed with all siRNAs in both of the breast can-
cer cell lines [see Additional File 1].
Rapamycin and Ly294002 block Thr389 phosphorylation 
of p70S6K
To further study the downstream targets of PI3K/mTOR
pathway, five breast cancer cell lines BT-474, MCF-7,
MDA-361, MDA-436 and SK-BR-3 were treated with PI3K
inhibitor Ly294002 and mTOR inhibitor rapamycin (Fig-
ure 1). We first evaluated the phosphorylation status of
p70S6K after inhibitor treatments by Western blotting.
Previously, we have shown [2,3] that MCF-7, BT-474 and
MDA-361 breast cancer cell lines have p70S6K amplifica-
tion and protein overexpression, whereas SK-BR-3 showBMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
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normal copy number and protein expression levels of
p70S6K. After the inhibitor treatments with Ly294002
and rapamycin, significantly lower or no protein expres-
sion of Thr389-phosphorylated p70S6K was detected by
Western blotting in all the rapamycin- and Ly294002-
treated breast cancer cell lines as compared to non-treated
samples (Figure 3A–B). Our results indicate that rapamy-
cin and Ly294002 blocked phosphorylation of Thr389,
one of the amino acids essential for p70S6K activation.
The total p70S6K levels were higher in MCF-7, MDA-361
and BT-474 breast cancer cell lines as compared to that of
SK-BR-3 (Figure 3A–B). In MDA-436 breast cancer cell
line, the expression of total p70S6K was hardly detectable
(data not shown).
Ly294002 and rapamycin treatments induce similar gene 
expression profiles with different biological outcomes
We then studied gene expression alterations caused by
inhibition of PI3K/mTOR pathway by PI3K inhibitor
Ly294002 and mTOR inhibitor rapamycin. SOM analysis
was performed in order to detect the overall gene expres-
sion alterations in five inhibitor-treated breast cancer cell
lines. In 24 h and 48 h time point treatments, 537 and 577
genes were differentially expressed in Ly294002-treated
Interfering the PI3K/mTOR/p70S6K signaling pathway Figure 1
Interfering the PI3K/mTOR/p70S6K signaling pathway. Schematic representation of the PI3K/mTOR/p70S6K pathway 
illustrates that p70S6K is located downstream of PI3K and mTOR. In this study, PI3K was inhibited with Ly294002, mTOR with 
rapamycin and p70S6K with siRNAs targeting RPS6KB1.
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cells and 538 and 523 genes were differentially expressed
in rapamycin-treated cells, respectively [see Additional
File 2]. Altogether, 38% of the differentially expressed
genes were altered in both the Ly294002 and rapamycin
treatments at 24 h time point. Additionally, several genes
associated with PI3K/mTOR pathway were altered at the
transcriptional level [see Additional File 2]. For example,
AKT1, FRAP1, EIF4E, EIF4G1, EIF4A1 and EIF4A2 were
transcriptionally altered in several inhibitor-treated cell
lines but not in cell lines treated with siRNAs targeting
RPS6KB1  [see Additional Files 1 and 2]. The protein
expression of three of these genes, AKT1,  FRAP1  and
EIF4G1 (encoding AKT, mTOR and eIF4G1, respectively),
were detected by Western immunoblotting and eIF4G1
showed downregulation at protein level by both rapamy-
cin and Ly294002 treatments (Figure 4A–B). To evaluate
the biological responses to PI3K/mTOR pathway inhibi-
tors, cell cycle and apoptosis assays were performed for
inhibitor-treated breast cancer cell lines. Ly294002 treat-
ment caused apoptosis in BT-474 and MDA-361 (Figure
5A–B) and G1 arrest of the cell cycle in MCF-7 and SK-BR-
3 breast cancer cell lines [see Additional File 3]. Rapamy-
cin arrested cells in G1 phase in three cell lines (MCF-7,
BT-474 and MDA-361) after 24 h or 48 h treatment [see
Additional File 3] without inducing apoptosis in any of
the cell lines (Figure 5A–B). The suppression of p70S6K
with RPS6KB1 siRNAs did not induce apoptosis (Figure
5C).
Genes responsive to both PI3K/mTOR pathway and 
p70S6K inhibitions reveal novel putative downstream 
targets of PI3K/mTOR/p70S6K pathway
We also compared the individual gene expression profiles
between Ly294002- and rapamycin-treated and RPS6KB1-
suppressed BT-474 and MCF-7 breast cancer cell lines to
identify genes downstream of PI3K/mTOR/p70S6K path-
way. Expression of 17 genes was altered in BT-474 and
MCF-7 breast cancer cell lines in response to both PI3K or
mTOR inhibition and p70S6K inhibition with at least two
siRNAs (Table 1). In BT-474 cell line, these included 9
genes, e.g. ARL11 and CDKN2B. Also in MCF-7 cell line, 9
genes were differentially expressed after siRNA and inhib-
itor treatments including VTCN1,  SCD  and  RELB.
ST3GAL6 was differentially expressed in both cell lines.
Altogether, the inhibition of PI3K and mTOR in BT-474
and MCF-7 cells by Ly294002 and rapamycin led to differ-
ential expression of a higher number of genes than with
Protein-level validation of p70S6K suppression after RPS6KB1  siRNA treatments in breast cancer cell lines Figure 2
Protein-level validation of p70S6K suppression after 
RPS6KB1 siRNA treatments in breast cancer cell 
lines. BT-474 and MCF-7 cells were treated with three siR-
NAs against RPS6KB1 and one scramble oligo for 72 hours 
and the protein expressions were detected by Western 
immunoblotting. The p70S6K expression was significantly 
downregulated in siRNA-transfected samples when com-
pared to the scramble oligo transfected samples. Beta-actin 
was used as a loading control.
Effects of rapamycin and Ly294002 treatments on phosphorylation of p70S6KThr389 in breast cancer cell lines Figure 3
Effects of rapamycin and Ly294002 treatments on phosphorylation of p70S6KThr389 in breast cancer cell lines. 
The cells were treated with A) 100 nM rapamycin and B) 50 μM Ly294002 for 24 hours and the phosphorylation status of 
p70S6K Thr389 was detected by Western immunoblotting. The plus (+) sign indicates the inhibitor-treated samples and the 
minus (-) sign the non-treated samples. Both rapamycin and Ly294002 blocked Thr389 phosphorylation of p70S6K. The total 
p70S6K expression was used as a reference.
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RPS6KB1 siRNAs [see Additional File 4]. The number of
differentially expressed genes after Ly294002 treatment
was 530, whereas after rapamycin treatment it was 117.
The higher number of genes after Ly294002 treatment is
somewhat expected since Ly294002 inhibition caused the
most effective biological response (Figure 5, see Addi-
tional File 3). Knock-down of p70S6K caused differential
expression of only 68 genes [see Additional Files 1 and 4]
and no apoptosis was detected in BT-474 and MCF-7 cell
lines (Figure 5).
Gene ontology (GO) analysis and Connectivity Map 
support the known effects of Ly294002 and rapamycin as 
well as suggest new inhibitors with similar mechanism of 
action
We then explored which gene ontology classes were
enriched in gene expression profiles of five Ly294002-
and rapamycin-treated breast cancer cell lines [see Addi-
tional File 5] by using Gene Ontology Categorizer [17].
Among the twenty relatively most enriched GO classes in
Ly294002-treated cell lines were functional categories
involved in cell killing, mitosis, and G1 phase of the cell
cycle. In rapamycin treatment, these included functional
categories such as mitosis, M phase of mitotic cell cycle
and translational elongation. To identify other clinically
approved drugs with potentially similar mechanisms of
action, we took advantage of the recently published Con-
nectivity Map [18], where connections of chemical or bio-
logical perturbations can be identified using a web-based
interface. As expected, Ly294002 gave the highest positive
connectivity for Ly294002-treated samples. Similarly,
rapamycin gave a high positive connectivity with fairly
low p-values (<0.059) for rapamycin-treated samples. The
novel drugs with high positive connectivity with our
Ly294002- and rapamycin-treated gene expression pro-
files included wortmannin, trichostatin A, and rottlerin.
Discussion
The 17q23 region is one of the most highly amplified
regions in breast cancer and RPS6KB1 is considered one of
its target genes [4,19]. Due to RPS6KB1 amplification and
overexpression in breast cancer and the role of p70S6K as
a downstream mediator of PI3K/mTOR pathway, our aim
was to identify PI3K/mTOR/p70S6K pathway down-
stream targets using gene expression profiling for breast
cancer cell lines that we have previously characterized in
regard to copy number and gene expression [4,19]. Five
breast cancer cell lines were treated with PI3K/mTOR
pathway inhibitors, including two cell lines that were also
inhibited with three RPS6KB1 siRNAs, since these two cell
lines show a high-level expression of p70S6K. The gene
expression signatures responsive to both PI3K/mTOR
pathway and p70S6K inhibitions revealed previously uni-
dentified genes suggesting novel downstream targets for
PI3K/mTOR/p70S6K pathway.
The PI3K pathway is deregulated in a number of cancers
and clinical trials are currently attempting to target differ-
ent components of this pathway [12]. The activation of
PI3K pathway is associated with aggressive breast cancer
and therefore, identification of its downstream targets
may have diagnostic value [20]. Since p70S6K is a down-
stream mediator of PI3K pathway, we explored gene
expression alterations caused by both p70S6K and PI3K/
mTOR pathway inhibitions. Altogether, expression levels
of 17 genes were altered in both RPS6KB1-suppressed and
inhibitor-treated samples, including VTCN1/B7-H4,
CDKN2B, SCD and ARL11. Especially, the down-regula-
tion of VTCN1/B7-H4 is interesting, since it has recently
been found to be overexpressed in a number of cancers
and have also been linked to poor prognosis [21,22]. The
expression of B7-H1, which is a member of the same pro-
tein family, has been shown to be increased due to loss of
PTEN and activation of PI3K pathway, linking PTEN with
immunoresistance mediated in part by B7-H1 [23]. The
down-regulation of VTCN1/B7-H4 due to Ly294002 treat-
ment suggests that similar to B7-H1, B7-H4 is also regu-
lated by PI3K. CDKN2B, encoding for cyclin-dependent
kinase inhibitor 2B, was up-regulated after mTOR and
p70S6K inhibitions in BT-474. Similarly, CDKN2A, was
up-regulated in MCF-7 in response to p70S6K suppres-
sion but not with inhibition of mTOR. The p16/p15 pro-
teins encoded by CDKN2A/CDKN2B  are known to be
associated with telomerase activation and cancer progres-
sion [24,25] as well as to induce cell cycle arrest by inhibi-
tion of CDK4 kinase [26]. Interestingly, mTOR inhibition
caused significant down-regulation of CCND1 suggesting
that cell cycle arrest could be caused by either down- or
Protein-level downregulation of eIF4G1 in rapamycin-treated  BT-474 cells and in Ly294002-treated SK-BR-3 cells Figure 4
Protein-level downregulation of eIF4G1 in rapamy-
cin-treated BT-474 cells and in Ly294002-treated SK-
BR-3 cells. The breast cancer cells were treated with 100 
nM rapamycin and 50 μM Ly294002 for 24 hours and the 
protein expression of eIF4G1 was detected by Western 
immunoblotting. The plus (+) sign indicates the inhibitor-
treated sample and the minus (-) sign the non-treated sam-
ple. A) Rapamycin and B) Ly294002 downregulated eIF4G1 
expression at protein level in BT-474 and SK-BR-3 cells, 
respectively. Beta-actin was used as a loading control.
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up-regulation of genes activating or inhibiting CDK4.
Additionally, SCD was down-regulated after mTOR inhi-
bition with rapamycin and p70S6K suppression with
RPS6KB1 siRNAs. SCD encodes stearoyl-CoA desaturase,
which has been suggested to promote cell proliferation,
invasion and inhibition of apoptosis [27]. Our finding of
SCD  as a potential downstream target of PI3K/mTOR/
p70S6K pathway is supported by the study of Chang et al.,
which reported that SCD is activated by PI3K and inhib-
ited by Ly294002 [28]. Most of the genes identified in our
study did not have any previous interaction with PI3K/
mTOR/p70S6K pathway. For example, ARL11, a gene with
Effects of rapamycin, Ly294002 and RPS6KB1 siRNA treatments on apoptosis of breast cancer cell lines Figure 5
Effects of rapamycin, Ly294002 and RPS6KB1 siRNA treatments on apoptosis of breast cancer cell lines. A) The 
cells were treated with 100 nM rapamycin and 50 μM Ly294002 for 48 hours and the cell morphology was evaluated under the 
light microscope. B) Caspase-3 activity assay of rapamycin- and Ly294002-treated breast cancer cell lines. C) Caspase-3 activity 
assay of RPS6KB1 siRNA-treated breast cancer cell lines. The values are averages from two or three independent experiments. 
Ly294002 induced apoptosis in BT-474 and MDA-361 breast cancer cells, whereas rapamycin had no effect. Similarly, knock-
down of RPS6KB1 did not have any effect on apoptosis in BT-474 and MCF-7 breast cancer cells.
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recently identified tumor suppressor function [29], was
up-regulated after both inhibiting PI3K and suppression
of p70S6K. Taken together, our study suggests many novel
targets potentially regulated by PI3K/mTOR/p70S6K
pathway.
Overall, the number of overlapping genes between three
treatments was small, which is expected, since all the
inhibitors have different targets with cross-talk also with
multiple other pathways. In addition to these biological
reasons, there are technical differences that are likely to
cause variability for gene expression changes caused by
different inhibitors. These include different specificities,
efficiencies and mechanisms of action of the treatments as
well as differences in assay platforms. For example,
Ly294002 is not exclusively selective for the PI3Ks, but is
known to inhibit also other lipid kinases than just PI3K
[30]. Secondly, possible off-target effects of RPS6KB1
siRNA knock-down or the fact that knock-down mainly
resulted in 70% decrease in mRNA levels are possible rea-
sons for variability between different experiments. Finally,
inhibitor-treated samples were studied using a 17 K gene
expression microarray platform, whereas siRNA-treated
samples were hybridized on a 44 K microarray platform
causing slight differences in the gene content of these two
microarray platforms. To minimize the above-mentioned
effects, we took into account only those genes that were
differentially expressed by at least two different siRNAs
and correlated this information with genes responsive to
PI3K and/or mTOR inhibition. This led to the identifica-
tion of 17 genes that are potential targets of PI3K/mTOR/
p70S6K pathway.
Since PI3K/mTOR pathway has a central role in cell sur-
vival and p70S6 kinase is an important regulator of cell
cycle progression through the G1/S point, we further stud-
ied the effect of Ly294002 and rapamycin on apoptosis
and cell cycle. Ly294002 treatment, but not rapamycin,
induced apoptosis of the breast cancer cell lines, which
may be due to a number of different reasons. Ly294002
inhibits PI3K that further regulates AKT, which has a
number of targets that are involved in cell death and sur-
vival [5]. In contrast, rapamycin inhibits mTOR, which is
located downstream of AKT and therefore, AKT mediated
effects on apoptosis should not be detected after rapamy-
cin treatment. Additionally, mTOR has been shown to be
involved in Notch1-mediated inhibition of p53-induced
apoptosis [31]. Since the majority of the breast cancer cell
lines used in this study carry a mutated form of p53 [32-
35], inhibition of mTOR by rapamycin should not affect
Table 1: Genes responsive to PI3K, mTOR and p70S6K inhibitions in breast cancer cell lines.
BT-474 breast cancer cell line, RPS6KB1-suppressed
Gene Name Description Inhibitor Expression
ARL11 ADP-ribosylation factor-like 11 Ly294002 U
B2M beta-2-microglobulin Ly294002 U
CECR1 cat eye syndrome chromosome region, candidate 1, transcript variant 1 Ly294002 U
PCDH10 protocadherin 10, transcript variant 1 Ly294002 U
PCDH11Y protocadherin 11 Y-linked, transcript variant c Ly294002 U
PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B, transcript variant 3 Ly294002 U
PSORS1C1 psoriasis susceptibility 1 candidate 1 Ly294002 U
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 Ly294002 rapamycin U
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4), transcript variant 1 rapamycin U
MCF-7 breast cancer cell line, RPS6KB1-suppressed
Gene Name Description Inhibitor Expression
COL5A1 collagen, type V, alpha 1 Ly294002 U
FAM5C family with sequence similarity 5, member C Ly294002 U
RELB v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3 (avian)
Ly294002 U
SOX15 SRY (sex determining region Y)-box 15 Ly294002 U
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 Ly294002 U
VTCN1 V-set domain containing T cell activation inhibitor 1 Ly294002 D
IFI44L interferon-induced protein 44-like rapamycin D
OASL 2'-5'-oligoadenylate synthetase-like, transcript variant 1 rapamycin D
SCD stearoyl-CoA desaturase (delta-9-desaturase) rapamycin D
The genes were differentially expressed to the same direction by small molecule inhibitors and at least two RPS6KB1 siRNAs.
Abbreviations: D = downregulated expression, U = upregulated expression.BMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
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on p53-induced cell death. Rapamycin also inhibits the
phosphorylation and activation of p70S6K through
mTOR inhibition. It has been observed that the breast
cancer cell lines with an amplification of RPS6KB1 are
more sensitive to rapamycin than cells with no amplifica-
tion [36]. Indeed, also in our study, the breast cancer cell
lines BT-474, MCF-7 and MDA-361, which have an ampli-
fication of RPS6KB1, seemed to be sensitive to the
rapamycin-induced G1 phase arrest. MCF-7 and BT-474
breast cancer cell lines have mutated forms of PIK3CA
[37,38], which can render these cells resistant to
Ly294002-mediated cell cycle arrest. Surprisingly,
Ly294002 treatment resulted in G1 arrest in MCF-7 cells
in addition to SK-BR-3 cell line. This discrepancy might be
explained by the possibility that MCF-7 cell line harbor
mutation with no activating function of PI3K. In contrast,
no arrest was detected in BT-474, MDA-361 and MDA-436
cells. Taken together, our results confirm the previously
observed effects of these inhibitors on cell cycle and sug-
gest that different breast cancer cell lines have different
biological responses to PI3K/mTOR pathway inhibitors;
especially MDA-436 seems to be resistant to rapamycin-
and Ly294002-induced cell cycle arrest.
The inhibition of PI3K/mTOR pathway with Ly294002
and rapamycin led to similar gene expression alterations
in different breast cancer cell lines. Altogether, 38% of the
differentially expressed genes were altered by both treat-
ments. Additionally, a number of genes known to be asso-
ciated with PI3K/mTOR pathway were differentially
expressed. For example, the down-regulation of eIF4G1 in
response to rapamycin and Ly294002 treatments was also
shown at protein level. This suggests that PI3K/mTOR
pathway inhibition leads to the transcriptional deregula-
tion of a number of critical components of the transla-
tional machinery. Unlike with PI3K or mTOR inhibition,
direct suppression of p70S6K did not seem to down-regu-
late genes involved in eIF-4F initiation complex. This
might be due to the fact that p70S6K is known to regulate
the rate of translation of transcripts encoding elongation
factors and ribosomal proteins [6], but inhibition of
p70S6K do not affect on transcriptional activation of these
genes. Gene Ontology Categorizer [17] and recently pub-
lished Connectivity Map [18] were further used to explore
the biological processes affected by PI3K/mTOR pathway
inhibition and drugs with similar mechanism of action.
Indeed, GO categories involved in cell killing, mitosis,
and G1 phase of the cell cycle were enriched in Ly294002-
treated cells, whereas functional categories like mitosis
and translational elongation were among the most
enriched classes with lowest p-values in rapamycin-
treated cells. Also Connectivity Map gave the highest
scores for Ly294002 and rapamycin in the breast cancer
cell lines treated with these inhibitors further validating
the gene expression profiles responsive to these PI3K and
mTOR inhibitors. Also wortmannin scored high in Con-
nectivity Map, which is expected, due to its mechanism as
a PI3K inhibitor. Other drugs with high statistical signifi-
cance included rottlerin, a protein kinase inhibitor, and
trichostatin A, a known HDAC inhibitor, both of which
are known to inhibit proteins interacting with PI3K/
mTOR pathway.
A number of studies have tried to find markers for path-
way activation, since activation of PI3K/AKT/mTOR path-
way is known to be associated with aggressive cancer.
Cancer drugs are increasingly designed to target specific
signaling pathways and also in this regard microarrays
have been used to identify oncogenic signatures aiming to
determine the activation state of specific pathways [39].
Recently, Saal et al. identified a new marker stathmin
(STMN1) to be associated with PTEN mutation and PI3K
activation in breast cancer. Stathmin was also found to be
down-regulated due to Ly294002 treatment [20] that is in
line with our data [see Additional File 2]. Recently, a tran-
scriptional signature specific for AKT1 activation and sub-
sequent mTOR inhibitor RAD001 treatment was
identified in luminal epithelial cells of the mouse ventral
prostate [40]. In another recent study, the presence of this
transcriptional signature was evaluated in five publicly
available microarray data sets from clinical breast tumors
[41]. Altogether, 57 AKT1-signature genes had p-values
less than 0.01 in three breast cancer data sets, from which
34 genes were regarded as RAD001-insensitive and 23
genes as RAD001-sensitive. We also evaluated whether
these genes would be differentially expressed in response
to rapamycin treatment in our study. Interestingly, 21%
(7/34) of the genes that positively correlated with AKT1
expression in a study by Creighton and co-workers, corre-
lated positively with AKT1 expression also in our rapamy-
cin-treated breast cancer cell lines. However, in
Creighton's study, the expression of these genes did not
change due to RAD001 treatment and therefore, these
genes were considered RAD001-insensitive. In our data,
these genes were down-regulated due to rapamycin treat-
ment opposite to the observation in clinical breast
tumors, in which these genes were up-regulated together
with AKT1. These results support the idea that these genes
are co-expressed with AKT1, although based on our data
their role in rapamycin sensitivity could not be confirmed.
In the present study, we took the approach to assess tran-
scriptional alterations in response to inhibition of PI3K/
mTOR/p70S6K pathway in breast cancer cell lines with
known gene copy number and gene expression altera-
tions, since RPS6KB1 encoding p70S6K is one of the most
highly amplified and overexpressed genes in breast can-
cer. The inhibition of PI3K/mTOR pathway by small mol-
ecule inhibitors led to similar gene expression alterations
across several breast cancer cell lines with different biolog-BMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
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ical outcomes. Since no specific inhibitor for p70S6K is
currently available, we prompted to use three different
RPS6KB1 siRNAs for inhibition of p70S6K in cell lines
with high-level amplification and overexpression of
RPS6KB1. Altogether, 109 and 173 genes were differen-
tially expressed in two RPS6KB1-suppressed breast cancer
cell lines, including 68 genes of which expression was
altered in both cell lines and 17 genes that overlapped
with genes differentially expressed after the small mole-
cule inhibitor treatments. We suggest that these 17 genes
that were differentially expressed after both PI3K or
mTOR inhibitions and p70S6K inhibition with at least
two siRNAs against RPS6KB1 are potential downstream
targets of PI3K/mTOR/p70S6K pathway.
Conclusion
We identified a number of genes that were differentially
expressed due to p70S6K suppression and PI3K/mTOR
pathway inhibitions suggesting novel downstream targets
of PI3K/mTOR/p70S6K pathway. These include VTCN1
and  CDKN2B, whose functional role in breast cancer
downstream of this pathway requires further investiga-
tion. Due to the association of p70S6K overexpression
with aggressive disease and poor prognosis of breast can-
cer patients, the downstream targets of p70S6K may have
diagnostic value.
Methods
Suppression of RPS6KB1 expression by siRNAs
BT-474 and MCF-7 breast cancer cell lines with high-level
amplification and overexpression of RPS6KB1  [4] were
transfected with three synthetic siRNAs targeting RPS6KB1
[GenBank: NM_003161]: siRNA 1 (siRNA ID#: 1454,
sense strand: 5'-GGACAUGGCAGGAGUGUUUtt-3', anti-
sense strand: 5'-AAACACUCCUGCCAUGUCCtc-3'),
siRNA 2 (siRNA ID#: 142750, sense strand: 5'-GCUACU-
UCGGGUACUUGGUtt-3', antisense strand: 5'-ACCAA-
GUACCCGAAGUAGCtc-3') and siRNA 3 (siRNA ID#:
110802): sense strand 5'-GGUCAUGUGAAAC-
UAACAGtt-3', antisense strand 5'-CUGUUAGUUU-
CACAUGACCtt-3') purchased from Ambion®  (Austin,
TX). Transfections were performed using the "Transfecting
Stealth™ RNA or siRNA into Mammalian Cells Using
Lipofectamine™ 2000" protocol according to the manu-
facturer's recommendations (Invitrogen, Carlsbad, CA).
150,000 cells per well were plated in 2.5 ml of culture
medium onto a 6-well plate 24 hours before the siRNA
transfections. For BT-474 cell line, 7.5 μl of
Lipofectamine2000 transfection reagent (Invitrogen) and
50 pmol of RPS6KB1 siRNA were used. For MCF-7 cell
line, the conditions were 7.5 μl of Lipofectamine2000 and
200 pmol of siRNA. After four hours of transfection, the
cell culture medium was replaced with fresh medium and
the cells were incubated altogether for 72 hours. The cells
from two parallel wells were pooled and the total RNAs of
BT-474 and MCF-7 breast cancer cell lines were isolated
using Qiagen RNeasy Mini Kit (QIAGEN, Valencia, CA).
The quality of the RNA was assessed by 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA) to control the integ-
rity of the samples before microarray hybridizations.
Inhibition of PI3K/mTOR pathway by small molecule 
inhibitors
Five breast cancer cell lines, BT-474, MCF-7, MDA-MB-
361, MDA-MB-436, and SK-BR-3, were treated with 50 μM
of PI3K inhibitor Ly294002 (Cell Signaling Technology,
Danvers, MA) and 100 nM of mTOR inhibitor rapamycin
(Calbiochem, Darmstadt, Germany) and the cells were
harvested at 24 h and 48 h time points. The cell lines were
purchased from ATCC and cultured according to the rec-
ommended conditions. The RNA was extracted using TRI-
zol® reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. After the Trizol extraction,
the RNAs were purified using Qiagen's (Valencia, CA)
RNeasy column purification to remove remnants from
Trizol extraction. Then, all the RNAs were run by 2100
Bioanalyzer (Agilent) before microarray hybridizations.
Protein assays by Western immunoblotting
Western immunoblotting was carried out to study the pro-
tein levels of p70S6K, AKT, mTOR and eIF4G1 after the
perturbation of the breast cancer cells with PI3K/mTOR
pathway inhibitors or RPS6KB1  siRNAs. Additionally,
phosphorylation of p70S6K was determined in
Ly294002- and rapamycin-treated cells to study whether
the inhibitors blocked the phosphorylation of p70S6K
Thr389. The inhibitor- and siRNA-treated cells harvested
at the time points were lysed with 150 μl of boiling hot
SDS lysis buffer (2.5 ml 20% SDS, 5 ml 1 M Tris pH 6.8,
12.5 ml dH2O) per well on a 6-well plate. The downregu-
lation of p70S6K was detected with rabbit p70S6 kinase
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in
1:1000 dilution and rabbit β-actin antibody (1:1000, Cell
Signaling, Danvers, MA) was used to detect the equal
loading of samples. The effect of the inhibitors on p70S6K
phosphorylation was studied using rabbit p-p70S6 kinase
antibody for Thr389 phosphorylation (Santa Cruz Bio-
technology) in 1:1000 dilution. The total protein amount
of p70S6 kinase was studied as above. We also performed
protein-level validation of the microarray results with the
following antibodies: Akt (1:1000, Cell Signaling), mTOR
(1:500, Cell Signaling), and eIF4G1 (1:500, Abcam, Cam-
bridge, UK). The detection of the proteins was performed
using anti-rabbit secondary antibody (1:1000, Amersham
Biosciences, Pittsburgh, PA) and chemiluminescence by
ECL detection kit (Amersham Biosciences).
Apoptosis and cell cycle assays
Apoptosis and cell cycle assays were performed for inhib-
itor-treated breast cancer cell lines and their controls toBMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
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evaluate biological response to PI3K/mTOR pathway
inhibitors. To study whether the inhibitors or RPS6KB1
siRNAs induced apoptosis, caspase-3 activity was meas-
ured from 30 or 40 μg of protein from each inhibitor- and
siRNA-treated cell lines using colorimetric caspase-3 activ-
ity (Ac-DEVD-pNa cleavage) assay as described previously
[42]. Additionally, the morphology of the cells was evalu-
ated under the light microscope to determine the number
of apoptotic cells in inhibitor-treated cells as compared to
the untreated controls. For the cell cycle assays, cells were
grown in duplicates on 96-well cell culture plates and har-
vested at 24 h and 48 h time points. Trypsinized cells were
centrifuged 200 × g for 3 min and then treated with 170 μl
of cold 70% ethanol followed by incubation o/n in -
20°C. After the incubation, the cells were centrifuged for
3 min, the supernatant was removed and the cells were
stained with 80 μl of RNase A/propidium iodide in PBS
(30 μg/ml). The cells were then incubated at +37°C for 45
min and stored at +4°C until they were analyzed using BD
FACSArray Bioanalyzer System (BD Biosciences, San Jose,
CA). An average of 15,000 events was analyzed per each
well.
Gene expression analysis by oligonucleotide microarrays
Microarray analyses from inhibitor-treated cell lines were
performed using Agilent's Human 1A Oligo Microarrays
containing 17,986 genes or transcripts. The inhibitor-
treated samples were hybridized against the correspond-
ing untreated cell line harvested at 24 h and 48 h time
points. The labeling was performed from 20 μg of total
RNA using direct labeling method according to the man-
ufacturer's instructions (Agilent Technologies). The RNAs
extracted from the RPS6KB1  siRNA-suppressed BT-474
and MCF-7 cell lines were hybridized against their corre-
sponding control cell lines transfected with siRNA Scram-
ble Duplex (Dharmacon Research Inc., Boulder, CO)
using identical conditions as with RPS6KB1 siRNA. Five-
hundred nanograms of total RNA was labeled according
to the manufacturer's recommendations (Agilent Tech-
nologies). The RNAs were hybridized on Agilent's Human
4x44K Oligo Microarrays containing 45,220 features. Two
technical replicates were performed for each hybridiza-
tion and the logarithmic transformed (base 10) mean
gene expression ratios were taken for further analysis. Pre-
processing of the data was performed by Feature Extrac-
tion software (v 6.1.1 and 9.5.3.1 for inhibitor- and
siRNA-treated samples, respectively). Only those genes,
for which the mean signal log 10 ratio from inhibitor-
treated cell lines or the two siRNA-suppressed replicates
was ≥ 0.3 or ≤ -0.3 with p values ≤ 0.05 representing two-
fold up- or down-regulation, respectively, were consid-
ered differentially expressed. The data from the inhibitor-
treated and the siRNA-transfected samples were analyzed
separately due to different processing of the samples. All
the raw data is available at CanGEM (please see Availabil-
ity & requirements for more information).
SOM (self-organizing map) clustering of inhibitor-
responsive gene expression signatures
To further study the genes that were identified as differen-
tially expressed due to PI3K/mTOR pathway inhibition
across all treated breast cancer cell lines, SOM clustering
algorithm with component plane presentation was used
to analyze and visualize the differences between the drug-
treated cell lines [43,44]. Only the differentially expressed
genes in each inhibitor treatment, whose standard devia-
tion (SD) was >3 in at least one of the samples, were
included into the clustering step. The SOM Toolbox for
MATLAB [45] was used with the following parameters:
sheet SOM map topology with batch learning, Euclidean
distance and Gaussian neighborhood function.
Gene Ontology mapping of inhibitor-responsive gene 
expression profiles
To highlight functionally important biological responses
to PI3K/mTOR pathway inhibitors, the representation of
gene ontology classes among differentially expressed
genes (SD>3) in inhibitor-treated breast cancer cell lines
was explored using The Gene Ontology Categorizer [17].
First, the updated Ensembl IDs (please see Availability &
requirements for more information) were retrieved for all
the genes with SD>3 among rapamycin and Ly294002
treatments. The GO classes were first sorted by their rela-
tive enrichment. Twenty most enriched GO classes were
then sorted according to their p-values of relative enrich-
ment [17].
Similarity search of inhibitor-induced gene expression 
profiles by Connectivity Map
To study whether other small molecules would cause sim-
ilar transcriptional alterations in human cell lines, the
inhibitor-perturbed gene expression data was down-
loaded into the Connectivity Map, which is a web-based
catalogue of gene expression data from chemically treated
cultured human cells [18]. The Agilent probe IDs were
first transformed into Affymetrix probe IDs using
Ensembl (please see Availability & requirements for more
information). The gene lists containing a maximum of
1000 up- and downregulated genes were loaded into the
Connectivity Map (please see Availability & requirements
for more information). The drugs giving the highest scores
for similarity with rapamycin- or Ly294002-treated breast
cancer cells were regarded as inhibitors with similar mech-
anisms of action.
Abbreviations
GO: gene ontology; mTOR: mammalian target of rapamy-
cin; p70S6K: 70 kDa ribosomal protein S6 kinase; PI3K:
phosphoinositide-3-kinase; SOM: self-organizing mapBMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
Page 11 of 12
(page number not for citation purposes)
Availability & requirements
CanGEM: http://www.cangem.org
Ensembl: http://www.ensembl.org
Broad Institute, Connectivity Map: http://
www.broad.mit.edu/cmap/
Authors' contributions
OM designed and supervised the study. HH performed
the RNAi experiments, inhibitor treatments and Western
assays. AN and JK carried out the apoptosis analyses. HH,
MS and SH carried out the bioinformatics analysis of the
microarray data. AK was involved in setting up the study.
HH and OM wrote the manuscript. All the authors have
read and accepted the final version of the manuscript.
Additional material
Acknowledgements
Tuula Airaksinen, Jaakko Hulkkonen, Taru Perttula, Katri Pullinen and Päivi 
Tainola are acknowledged for excellent technical assistance. Biomedicum 
High-Throughput Center is acknowledged for running the FACSArray 
experiments. This study was supported by Academy of Finland, Finnish 
Cancer Organizations, Helsinki University Research Funds, Biocentrum 
Helsinki, Sigrid Juselius Foundation and HUS-EVO research funds.
References
1. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, James CD: Locali-
zation of PS6K to Chromosomal Region 17q23 and Determi-
nation of its Amplification in Breast Cancer.  Cancer Res 1999,
59:1408-1411.
2. Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML,
Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, Kallioniemi
A: Detecting Activation of Ribosomal Protein S6 Kinase by
Complementary DNA and Tissue Microarray Analysis.  J Natl
Cancer Inst 2000, 92:1252-1259.
3. Bärlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G,
Kallioniemi OP, Kallioniemi A: Multiple genes at 17q23 undergo
amplification and overexpression in breast cancer.  Cancer Res
2000, 60:5340-5344.
4. Monni O, Bärlund M, Mousses S, Kononen J, Sauter G, Heiskanen M,
Paavola P, Avela K, Chen Y, Bittner ML, Kallioniemi A: Comprehen-
sive copy number and gene expression profiling of the 17q23
amplicon in human breast cancer.  Proc Natl Acad Sci USA 2001,
98:5711-5716.
5. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the
PI3K/AKT pathway for cancer drug discovery.  Nat Rev Drug
Discov 2005, 4:988-1004.
6. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Tho-
mas G: Rapamycin suppresses 5'TOP mRNA translation
through inhibition of p70s6k.  EMBO J 1997, 16:3693-3704.
7. Loreni F, Thomas G, Amaldi F: Transcription inhibitors stimu-
late translation of 5' TOP mRNAs through activation of S6
kinase and the mTOR/FRAP signalling pathway.  Eur J Biochem
2000, 267:6594-6601.
8. Chou MM, Blenis J: The 70 kDa S6 kinase : regulation of a
kinase with multiple roles in mitogenic signalling.  Curr Opin
Cell Biol 1995, 7:806-814.
9. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G:
Drosophila S6 kinase: a regulator of cell size.  Science 1999,
285:2126-2129.
10. Radimerski T, Montagne J, Rintelen F, Stocker H, Kaay J van der,
Downes CP, Hafen E, Thomas G: dS6K-regulated cell growth is
dPKB/dPI(3)K-independent, but requires dPDK1.  Nat Cell Biol
2002, 4:251-255.
11. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ: p70S6
kinase signals cell survival as well as growth, inactivating the
pro-apoptotic molecule BAD.  Proc Natl Acad Sci USA 2001,
98:9666-9670.
12. Workman P: Inhibiting the phosphoinositide 3-kinase pathway
for cancer treatment.  Biochem Soc Trans 2004, 32:393-396.
13. Granville CA, Memmot RM, Gills JJ, Dennis PA: Handicapping the
Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/
Akt/Mammalian Target of Rapamycin Pathway.  Clin Cancer
Res 2006, 12:679-689.
14. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann
MP, Williams RL: Structural Determinants of
Phosphoinositide3-Kinase Inhibition by Wortmannin, LY29
Quercetin, Myricetin, and Staurosporine.  Mol Cell 4002,
6:909-919.
15. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J: Phospha-
tidic Acid- Mediated Mitogenic Activation of mTOR Signal-
ing.  Science 2001, 294:1942-1945.
16. Chen Y, Zheng Y, Foster DA: Phospholipase D confers rapamy-
cin resistance in human breast cancer cells.  Oncogene 2003,
22:3937-3942.
17. Joslyn CA, Mniszewski SM, Fulmer A, Heaton G: The gene ontol-
ogy categorizer.  Bioinformatics 2004, 20(Suppl 1):i169-i177.
18. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner
J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei
G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander
ES, Golub TR: The Connectivity Map: using gene-expression
signatures to connect small molecules, genes, and disease.
Science 2006, 313:1929-1935.
19. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozen-
blum E, Ringnér M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP,
Additional File 1
Differentially expressed genes after RPS6KB1 siRNA treatments in breast 
cancer cell lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-348-S1.xls]
Additional File 2
Differentially expressed genes after inhibitor treatments in breast cancer 
cell lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-348-S2.xls]
Additional File 3
Effects of Ly294002 and rapamycin treatments on cell cycle arrest in 
breast cancer cell lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-348-S3.xls]
Additional File 4
Common differentially expressed genes by inhibitor and siRNA treatments 
in BT-474 and MCF-7.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-348-S4.xls]
Additional File 5
Enriched gene ontology (GO) classes after Ly294002 and rapamycin 
treatments in breast cancer cell lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-348-S5.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2008, 9:348 http://www.biomedcentral.com/1471-2164/9/348
Page 12 of 12
(page number not for citation purposes)
Kallioniemi A: Impact of DNA Amplification on Gene Expres-
sion Patterns in Breast Cancer.  Cancer Res 2002, 62:6240-6245.
20. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer
M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl
PO, Rosen N, Hibshoosh H, Ringner M, Borg Å, Parsons R: Poor
prognosis in carcinoma is associated with a gene expression
signature of aberrant PTEN tumor suppressor pathway
activity.  Proc Natl Acad Sci USA 2007, 104:7564-7569.
21. Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R, Liu W,
Pilkington G, Papkoff J: The immunomodulatory protein B7-H4
is overexpressed in breast and ovarian cancers and pro-
motes epithelial cell transformation.  Exp Cell Res 2005,
306:128-141.
22. Krambeck AE, Houston Thompson R, Dong H, Lohse CM, Park ES,
Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED: B7-H4
expression in renal cell carcinoma and tumor vasculature:
Associations with cancer progression and survival.  Proc Natl
Acad Sci USA 2006, 103:10391-10396.
23. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ,
Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D,
Pieper RO: Loss of tumor suppressor PTEN function
increases B7-H1 expression and immunoresistance in gli-
oma.  Nat Med 2007, 13:84-88.
24. Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Boström
J, Löning T, Schramm J: Alterations of INK4ap16-p14ARF/INK4bp15
expression and telomerase activation in meningioma pro-
gression.  J Neurooncol 2001, 55:149-158.
25. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M,
Munakata A: Influence of methylated p15INK4b and p16INK4a
genes on clinicopathological features in colorectal cancer.  J
Gastroenterol Hepatol 2006, 21:1334-1339.
26. Wall SJ, Zhong ZD, DeClerck YA: The Cyclin-dependent Kinase
Inhibitors p15INK4B and p21CIP1 Are Critical Regulators of
Fibrillar Collagen-induced Tumor Cell Cycle Arrest.  J Biol
Chem 2007, 282:24471-24476.
27. Scaglia N, Caviglia JM, Igal RA: High stearoyl-CoA desaturase
protein and activity levels in simian virus 40 transformed-
human lung fibroblasts.  Biochim Biophys Acta 2005, 1687:141-151.
28. Chang Y, Wang J, Lu X, Thewke DP, Mason RJ: KGF induces lipo-
genic genes through a PI3K and JNK/SREBP-1 pathway in
H292 cells.  J Lipid Res 2005, 46:2624-2635.
29. Yendamuri S, Trapasso F, Ferracin M, Cesari R, Sevignani C, Shimizu
M, Rattan S, Kuroki T, Dumon KR, Bullrich F, Liu C, Negrini M, Wil-
liams NN, Kaiser LR, Croce CM, Calin GA: Tumor Suppressor
Functions of ARLTS1 in Lung Cancers.  Cancer Res 2007,
67:7738-7745.
30. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms
JF, Waterfield MD: Exploring the specificity of the PI3K family
inhibitor Ly294002.  Biochem J 2007, 404:15-21.
31. Mungamuri SK, Yang XH, Thor AD, Somasundaram K: Survival Sig-
naling by Notch1: Mammalian Target of Rapamycin
(mTOR)-Dependent Inhibition of p53.  Cancer Res 2006,
66:4715-4724.
32. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR: Com-
plex response of breast epithelial cell lines to topoisomerase
inhibitors.  Anticancer Res 1998, 18:2919-2932.
33. Brodowicz T, Kandioler D, Tomek S, Ludwig C, Rudas M, Kunstfeld
R, Koestler W, Hejna M, Budinsky A, Krainer M, Wiltschke C, Zielin-
ski CC: Anti-Her-2/neu antibody induces apoptosis in Her-2/
neu overexpressing breast cancer cells independently from
p53 status.  Br J Cancer 2001, 85:1764-1770.
34. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Poss-
inger K, Koeffler HP: Novel therapeutic approach: ligands for
PPARã and retinoid receptors induce apoptosis in bcl-2-pos-
itive human breast cancer cells.  Breast Cancer Res Treat 2002,
74:155-165.
35. Liang Y, Wu J, Stancel GM, Hyder SM: p53-dependent inhibition
of progesterin-induced VEGF expression in human breast
cells.  J Steroid Biochem 2005, 93:173-182.
36. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong JJ, Mills GB,
Hung MC, Meric-Bernstam F: Determinants of rapamycin sensi-
tivity in breast cancer cells.  Clin Cancer Res 2004, 10:1013-1023.
37. Tenorio GP, Alkhori L, Olsson B, Ahnström Waltersson M, Norden-
skjöld B, Rutqvist LE, Skoog L, Stål O: PIK3CA mutations and
PTEN loss correlate with similar prognostic factors and are
not mutually exclusive in breast cancer.  Clin Cancer Res 2007,
13:3577-3584.
38. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT,
Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell
MJ: The morphologies of breast cancer cell lines in three-
dimensional assays correlate with their profiles of gene
expression.  Molecular Oncology 2007, 1:84-96.
39. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Har-
pole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK,
West M, Nevins JR: Oncogenic pathway signatures in human
cancers as a guide to targeted therapies.  Nature 2006,
439:353-357.
40. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM,
Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA,
Sellers WR: mTOR inhibition reverses Akt-dependent pros-
tate intraepithelial neoplasia through regulation of apop-
totic and HIF-1-dependent pathways.  Nat Med 2004,
10:594-601.
41. Creighton CJ: A gene transcription signature of the Akt/
mTOR pathway in clinical breast tumors.  Oncogene 2007,
26:4648-4655.
42. Nieminen AI, Partanen JI, Hau A, Klefström J: c-Myc primed mito-
chondria determine cellular sensitivity to TRAIL-induced
apoptosis.  EMBO J 2007, 26:1055-1067.
43. Kohonen T: Self-Organizing Maps 3rd edition. Berlin, Germany:
Springer; 2001. 
44. Hautaniemi S, Yli-Harja O, Astola J, Kauraniemi P, Kallioniemi A, Wolf
M, Ruiz J, Mousses S, Kallioniemi OP: Analysis and visualization of
gene expression microarray data in human cancer using self-
organizing maps.  Mach Learn 2003, 52:45-66.
45. Vesanto J, Himberg J, Alhoniemi E, Parhankangas J: SOM toolbox for
Matlab 5.  In Technical Report A57 Helsinki University of Technology,
Finland; 2000. 